Result summary of first half of the year:

• Revenue HK$3,333 million, representing a drop of 2.1% (in terms of RMB, growth of 4.7%);
• Net profit HK$639 million, representing a growth of 12%;
• The Board resolved to pay interim dividend of HK$0.07 /share

HONG KONG SAR - Media OutReach - 29 August 2023 -SSY Group Limited ("SSY" or the "Company"; Stock Code: 2005.HK) and its subsidiaries (together, the "Group") presents the interim results of the Company for the six months ended 30 June 2023 ("first half of 2023" or "first half of the year"). During the first half of 2023, the Group achieved a revenue of approximately Renminbi ("RMB") 2,962 million, representing an increase of approximately 4.7% as compared to the corresponding period of last year. However, due to depreciation of Renminbi against Hong Kong dollars by approximately 6.5% as compared to the same period last year, in terms of Hong Kong dollars, the Group's revenue was approximately HK$3,333 million in the first half of this year, representing a decrease of 2.1% as compared to corresponding period of last year. The Group achieved a net profit of approximately HK$639 million, representing an increase of approximately 12% as compared to the corresponding period of last year. Confronted with the tough challenges in the domestic and international pharmaceutical markets, the Group was determined to be ambitious, seize the opportunities and overcome the difficulties. Through a series of operational measures such as accelerating research and development and innovation, integrating market resources and actively exploring potentials, the Group continued to maintain a favourable trend of stable and healthy development. The Board of directors resolved to pay an interim dividend of HK$0.07 per share for year 2023, which increased by 16.7% as compared to corresponding period of last year. The total amount to be paid is approximately HK$208 million. During the first half of the year, the cumulative sales volume of intravenous infusion solutions reached approximately 936 million bottles (bags), with a revenue of HK$2,069 million, representing an increase of approximately 24.1% and 12.8% respectively as compared to corresponding period of last year. Among which, production and sales of therapeutic infusion solutions progressed steadily with revenue amounted to HK$566 million, representing an increase of 24.7% as compared to corresponding period of last year. Exports of preparations to foreign countries rose against the trend, infusion solutions export revenue amounted to approximately HK$80.08 million, representing a growth of approximately 25% as compared to corresponding period of last year. Ampoule products recorded continuous growth in sales volume. In the first half of the year, sales volume reached approximately 131 million, representing a growth of approximately 92% as compared to corresponding period of last year. Oral preparations business segment accelerated its expansion and development. In the first half of the year, revenue reaching HK$244 million, representing a growth of approximately 68% as compared to corresponding period of last year. Due to the impacts of softer market demands and dropping market prices of bulk pharmaceuticals in the first half of the year, revenue was approximately HK$454 million, representing a decrease of approximately 42% as compared to corresponding period last year. External sales of medical materials in terms of Hong Kong dollar roughly at same level as corresponding period of last year. The Group has taken the innovation drive as the lead to integrate the Group's own advantages, and coordinated the progress to push forward the research and development of featured generic drugs, bulk pharmaceuticals, innovative drugs, medical materials as well as product types under consistency evaluation, in an effort to establish a new course and a new advantage in the development of featured generic drugs and high-end complex preparation. In the first half of the year, the Group was at the forefront of all pharmaceutical enterprises in China in terms of the number of preparations being submitted for approvals and passed the consistency evaluations, and obtained a total of 34 production approvals for different types, including 8 for bulk pharmaceuticals and 26 for preparations. As of the first half of the year, the number of the Group's products that have passed the consistency evaluation or been regarded as passing the consistency evaluation reached 51 product types with 67 specifications, which has seized opportunities for enhancing market competitiveness for the products. Positive progress has been made in the research of innovative drugs. Phase I clinical trial of type I chemical innovative anti-tumor drug NP-01 project had positive progress. Communication with CDE prior to application of the Phase I clinical trial regarding anti-liver fibrosis innovative drug ADN-9 has been established. Pre-clinical...